Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pan-tumor rollover study for long-term treatment after prior BMS nivolumab-based cancer trials
2023-506914-32-00Phase 2Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 28
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in cancer, Nonhematologic neoplasms and hematopoietic malignancies, sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of adverse events. Planned start May 2020; status: authorised.
02
Drugs
03
Conditions
cancerNonhematologic neoplasmshematopoietic malignancies
Beyond the preview
Go deeper on 2023-506914-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506914-32-00.